Generex announces publication of Li-Key research data

Canada's Generex Biotechnology Corp says that, in collaboration with France's Stallergenes and researchers at the USA's Johns Hopkins University, its immunotherapy-focused Antigen Express subsidiary has conducted work that confirms the mechanism of CD4+ T helper stimulation by Li-Key sequences. The findings, which are due to be published in the journal Molecular Immunology, support Antigen Express' use of Li-Key in the generation of immunogenic vaccine peptides for a variety of disease indications.

A second research project, also co-authored with Stallergenes, entitled Single cell assessment of allergen-specific T cell responses with MHC class II peptide tetramers: Methodological aspects, is scheduled for publication in the International Archives of Allergy and Immunology journal. Generex said that the work demonstrated that T helper cells activated in response to specific allergens can be identified ex vivo with a high degree of sensitivity using Li-Key hybrids. The firm added that, at present, this technique is being employed by Antigen Express to identify patients in the earliest stages of type 1 diabetes.